EXPEDITED PUBLICATION: COMMENTARY
COURAGE Under FireOn the Management of Stable Coronary Disease
George A. Diamond, MD, FACC* and
Sanjay Kaul, MD, FACC
Division of Cardiology, Cedars-Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California.
Manuscript received August 9, 2007;
revised manuscript received August 17, 2007,
accepted August 27, 2007.
* Reprint requests and correspondence: Dr. George A. Diamond, 2408 Wild Oak Drive, Los Angeles, California 90068. (Email: gadiamond{at}pol.net).
The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial showed that coronary interventional procedures added little to optimal medical therapy with respect to the long-term outcome of patients with stable coronary disease when used as initial therapy. Detractors opine that: 1) the trial was unrealistic in design and the findings were not unexpected; 2) the use of coronary interventional procedures was suboptimal; and 3) the results of COURAGE are not applicable to current clinical practice. We herein reevaluate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant new information to assist the practitioner in the appropriate management of patients with stable coronary disease
|
Abbreviations and Acronyms
| | DES = drug-eluting stent(s) | | MI = myocardial infarction | | NYHA = New York Heart Association | | OMT = optimal medical therapy | | PCI = percutaneous coronary intervention |
|
This article has been cited by other articles:

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
 |
|
|